共有 1 页
品牌 | 货号 | 包装单位 | 货期 | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|
罗恩 | R032709-1mg | 1mg | 现货 |
土大黄甙 GSK690693 |
99% |
|
|
阿拉丁 | G127527-10mg | 10mg | 现货 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G127527-50mg | 50mg | 现货 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G127527-5mg | 5mg | 现货 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G127527-100mg | 100mg | 现货 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK-690693 |
Moligand™, ≥98% |
|
|
阿拉丁 | G409035-1ml | 1ml | 现货 |
GSK690693 GSK690693 |
Moligand™, 10mM in DMSO |
|
|
凯为 | JZ00GSV7-1mg | 1mg | 期货,请咨询 |
土大黄甙 4-[2-(4-Amino-1,2,5-oxadiazo... |
99% |
|
|
凯为 | JZ00GSV7-5mg | 5mg | 期货,请咨询 |
土大黄甙 4-[2-(4-Amino-1,2,5-oxadiazo... |
99% |
|
|
凯为 | JZ00GSV7-10mg | 10mg | 期货,请咨询 |
土大黄甙 4-[2-(4-Amino-1,2,5-oxadiazo... |
99% |
|
|
毕得 | BD234847-5mg | 5mg | 现货 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-10mg | 10mg | 现货 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-50mg | 50mg | 现货 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-25mg | 25mg | 现货 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
毕得 | BD234847-1mg | 1mg | 现货 |
(S)-4-(2-(4-氨基-1,2,5-额二唑-3-基... (S)-4-(2-(4-Amino-1,2,5-oxad... |
99% |
|
|
韶远 | SY328472-0.05g | 0.05g | 现货 |
(S)-4-[2-(4-氨基-1,2,5-噁二唑-3-基... (S)-4-[2-(4-Amino-1,2,5-oxad... |
≥95% |
|
|
Matrix | MA096072-250mg | 250mg | 3-4周 |
(S)-4-(2-(4-Amino-1,2,5-oxad... (S)-4-(2-(4-Amino-1,2,5-oxad... |
95+% | 咨询 | 请联系客服购买! |
Matrix | MA096072-1g | 1g | 3-4周 |
(S)-4-(2-(4-Amino-1,2,5-oxad... (S)-4-(2-(4-Amino-1,2,5-oxad... |
95+% | 咨询 | 请联系客服购买! |
Sigma | SML0428-5MG | 5mg | 请咨询 |
GSK690693 GSK690693 |
≥98% (hplc)≥98% (HPLC) | 咨询 | 请联系客服购买! |
Sigma | SML0428-25MG | 25mg | 请咨询 |
GSK690693 GSK690693 |
≥98% (hplc)≥98% (HPLC) | 咨询 | 请联系客服购买! |
源叶 | S81130-5mg | 5mg | 期货,请咨询 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
源叶 | S81130-10mg | 10mg | 期货,请咨询 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
源叶 | S81130-50mg | 50mg | 期货,请咨询 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
源叶 | S81130-100mg | 100mg | 期货,请咨询 |
GSK690693,新型ATP竞争性泛Akt激酶抑制剂 GSK690693 |
≥98% |
|
|
源叶 | S59417-1ml | 1ml | 期货,请咨询 |
GSK690693 GSK690693 |
10mM in DMSO |
|
|
Target Mol | T6285-1mg | 1mg | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Target Mol | T6285-5mg | 5mg | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Target Mol | T6285-10mg | 10mg | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Target Mol | T6285-50mg | 50mg | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Target Mol | T6285-100mg | 100mg | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Target Mol | T6285-1mL | 1mL | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Target Mol | T6285-25mg | 25mg | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Target Mol | T6285-500mg | 500mg | 现货 |
化合物 GSK690693 GSK-690693 |
98.78% |
|
|
Am | A111141-10mg | 10mg | 现货 |
GSK-690693 GSK-690693 |
98+% |
|
|
Am | A111141-1mg | 1mg | 现货 |
GSK-690693 GSK-690693 |
98+% |
|
|
Am | A111141-50mg | 50mg | 现货 |
GSK-690693 GSK-690693 |
98+% |
|
|
Am | A111141-25mg | 25mg | 现货 |
GSK-690693 GSK-690693 |
98+% |
|
|
Am | A111141-100mg | 100mg | 现货 |
GSK-690693 GSK-690693 |
98+% |
|
|
Am | A111141-5mg | 5mg | 现货 |
GSK-690693 GSK-690693 |
98+% |
|
|
MCE | HY-10249-100mg | 100mg | 现货 |
GSK-690693 GSK-690693 |
98.46% |
|
|
MCE | HY-10249-50mg | 50mg | 现货 |
GSK-690693 GSK-690693 |
98.46% |
|
|
MCE | HY-10249-25mg | 25mg | 现货 |
GSK-690693 GSK-690693 |
98.46% |
|
|
MCE | HY-10249-10mg | 10mg | 现货 |
GSK-690693 GSK-690693 |
98.46% |
|
|
MCE | HY-10249-10mM*1mL | 10mM*1mL | 现货 |
GSK-690693 GSK-690693 |
98.46% |
|
|
MCE | HY-10249-5mg | 5mg | 现货 |
GSK-690693 GSK-690693 |
98.46% |
|
|
MCE | HY-10249-1mg | 1mg | 现货 |
GSK-690693 GSK-690693 |
98.46% |
|
|